Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05287750

Brain Diseases on 7.0T Magnetic Resonance Imaging

This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

7T MRI increased detection sensitivity, attain superior anatomic resolution, higher spatial and spectral specificity of advanced quantitative techniques, and shorter scan times than 3T MRI. When applied clinically, these benefits translate to increased detection sensitivity, and ultimately improved diagnostic and therapies confidence to inform decision making. This study aim to detect the image characteristics and diagnostic accuracy of brain diseases on 7T MRI.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age≥18 and ≤80
  • Having brain diseases (eg: brain tumor, cerebrovascular diseases)
  • Having no contraindications against MRI or intravenous contrast agent administration
  • Clinically stable

Exclusion criteria

  • Age<18 or >80
  • Pregnancy and other contraindication to MRI scan
  • Informed consent not obtained

Treatment and study plan

Magnetic Resonance Imaging

Diagnostic Test

Patients recruited will receive Magnetic resonance imaging.

Primary outcomes

  1. the correspondence between brain tumor cells found in the biopsies and region of interest(ROI) signal intension on the 7T MRI scan and 3T MRI scan

    Time frame: within a month after biopsy

    Pathological assessment of biopsy material compared with the lesion's contrast-enhancement signal intension to normal brain white mater on 7T MRI and 3T MRI

  2. The visibility of white matter tracts on 7T MRI

    Time frame: within a month after biopsy

    Visualization of white matter tracts will be done with the use of diffusion tensor imaging (DTI) on 7T MRI and measuring the mean diffusivity (MD) value on Post-processing workstation ,and analysis the correlation between these values and pathological.

Secondary outcomes

  1. The correlation between the ROI's signal intension on 7T MRI scan and the KPS in 1 month after operation

    Time frame: within a month after biopsy

    The correlation analysis between the T1 contrast-enchanced signal intension, Regional cerebral blood flow on 7T MRI (clinical sequence and perfusion) scan and the KPS in 1 month after operation

  2. The visibility of white matter tracts on 7T MRI and 3T MRI

    Time frame: Six months after the biopsy

    Visualization of white matter tracts will be done with the use of diffusion tensor imaging (DTI) on 7T MRI and 3T MRI. and analysis the difference of the mean diffusivity (MD) value between 7.0T MRI and 3.0T MRI

Study contacts

Contact information is provided by the study sponsor or research team.

Kun Cheng, M.S.

CONTACT

[email protected]

+86 19921784434

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Mar 18, 2022
Registry last updated
Mar 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.